Fig. 2
Overview of targets and diseases investigated in clinical trials. A Distribution of trials by molecular targets with each trial registering at least one target. Double targets are indicated and separated with “/”. B Overall disease groups that are addressed throughout the clinical trials. C Diseases targeted by CAR NK cell therapies^1, and colored by disease group. Note that multiple diseases can be registered for one trial. Trials terminated before first patient-enrollment are not included in the figures. D Targets distributed across the different diseases, with increasing bubble size indicating higher frequency. B-Lymphoma B cell Lymphoma (unspecified), AML Acute myeloid leukemia, B-ALL B cell Acute Lymphoblastic Leukemia, CLL Chronic Lymphocytic Leukemia, DLBCL Diffuse Large B cell Lymphoma, MCL Mantle Cell Lymphoma, HNSCC Head and Neck Squamous Cell Carcinoma, SLE Systemic Lupus Erythematosus, FL Follicular Lymphoma, GEJ Cancer Gastroesophageal Junction Adenocarcinoma, MDS Myelodysplastic Syndromes, Autoimmune Autoimmune diseases, unspecified, T-ALL T cell Acute Lymphoblastic Leukemia, T-Lymphoma T cell Lymphoma, unspecified, BPDCN Blastic Plasmacytoid Dendritic Cell Neoplasm, ITP Primary Immune Thrombocytopenia, mCRPC Metastatic Castration-Resistant Prostate Cancer, MZL Marginal Zone Lymphoma, PMBCL Primary Mediastinal Large B cell Lymphoma, WM Waldenströms Macroglobulinemia.